106 related articles for article (PubMed ID: 1438625)
1. Pupillary constriction during haloperidol treatment as a predictor of relapse following drug withdrawal in schizophrenic patients.
Steinhauer SR; van Kammen DP; Colbert K; Peters JL; Zubin J
Psychiatry Res; 1992 Sep; 43(3):287-98. PubMed ID: 1438625
[TBL] [Abstract][Full Text] [Related]
2. Plasma prolactin as a predictor of relapse in drug-free schizophrenic outpatients.
Kirkpatrick B; Carpenter WT; Maeda K; Buchanan RW; Breier A; Tamminga CA
Biol Psychiatry; 1992 Dec; 32(11):1049-54. PubMed ID: 1467385
[TBL] [Abstract][Full Text] [Related]
3. Changes in psychopathology and dyskinesia after neuroleptic withdrawal in a double-blind design.
Dixon L; Thaker G; Conley R; Ross D; Cascella N; Tamminga C
Schizophr Res; 1993 Oct; 10(3):267-71. PubMed ID: 8260445
[TBL] [Abstract][Full Text] [Related]
4. Noradrenergic activity and prediction of psychotic relapse following haloperidol withdrawal in schizophrenia.
van Kammen DP; Agren H; Yao JK; O'Connor DT; Gurklis J; Peters JL
Am J Psychiatry; 1994 Mar; 151(3):379-84. PubMed ID: 7509126
[TBL] [Abstract][Full Text] [Related]
5. Clinical predictors of relapse following neuroleptic withdrawal.
Buchanan RW; Kirkpatrick B; Summerfelt A; Hanlon TE; Levine J; Carpenter WT
Biol Psychiatry; 1992 Jul; 32(1):72-8. PubMed ID: 1356490
[TBL] [Abstract][Full Text] [Related]
6. Electroencephalographic sleep in clinically stable schizophrenic patients: two-weeks versus six-weeks neuroleptic-free.
Nofzinger EA; van Kammen DP; Gilbertson MW; Gurklis JA; Peters JL
Biol Psychiatry; 1993 Jun 1-15; 33(11-12):829-35. PubMed ID: 8104041
[TBL] [Abstract][Full Text] [Related]
7. Sleep in schizophrenic patients on and off haloperidol therapy. Clinically stable vs relapsed patients.
Neylan TC; van Kammen DP; Kelley ME; Peters JL
Arch Gen Psychiatry; 1992 Aug; 49(8):643-9. PubMed ID: 1637254
[TBL] [Abstract][Full Text] [Related]
8. CSF norepinephrine in schizophrenia is elevated prior to relapse after haloperidol withdrawal.
van Kammen DP; Peters J; van Kammen WB; Nugent A; Goetz KL; Yao J; Linnoila M
Biol Psychiatry; 1989 Jun; 26(2):176-88. PubMed ID: 2472177
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid corticotropin-releasing factor increases following haloperidol withdrawal in chronic schizophrenia.
Forman SD; Bissette G; Yao J; Nemeroff CB; van Kammen DP
Schizophr Res; 1994 Apr; 12(1):43-51. PubMed ID: 8018584
[TBL] [Abstract][Full Text] [Related]
10. Behavioral vs biochemical prediction of clinical stability following haloperidol withdrawal in schizophrenia.
van Kammen DP; Kelley ME; Gurklis JA; Gilbertson MW; Yao JK; Peters JL
Arch Gen Psychiatry; 1995 Aug; 52(8):673-8. PubMed ID: 7543265
[TBL] [Abstract][Full Text] [Related]
11. Predicting duration of clinical stability following haloperidol withdrawal in schizophrenic patients.
van Kammen DP; Kelley ME; Gurklis JA; Gilbertson MW; Yao JK; Condray R; Peters JL
Neuropsychopharmacology; 1996 Apr; 14(4):275-83. PubMed ID: 8924195
[TBL] [Abstract][Full Text] [Related]
12. Influence of haloperidol on the relationship of frontal lobe function to psychomotor poverty and disorganization syndromes.
Allen DN; Anastasiou A; Goldstein G; Gilbertson M; van Kammen DP
Psychiatry Res; 2000 Feb; 93(1):33-9. PubMed ID: 10699226
[TBL] [Abstract][Full Text] [Related]
13. Memory and plasma HVA changes in schizophrenia: are they episode markers?
Gilbertson MW; Yao JK; van Kammen DP
Biol Psychiatry; 1994 Feb; 35(3):203-6. PubMed ID: 8173021
[No Abstract] [Full Text] [Related]
14. [Zotepine: treatment of schizophrenic patients with predominantly negative symptoms. A double-blind study vs. haloperidol].
Barnas C; Stuppäck CH; Miller C; Haring C; Sperner-Unterweger B; Fleischhacker WW
Fortschr Neurol Psychiatr; 1991 Sep; 59 Suppl 1():36-40. PubMed ID: 1683338
[TBL] [Abstract][Full Text] [Related]
15. Stability of neurological signs with clozapine treatment.
Buchanan RW; Koeppl P; Breier A
Biol Psychiatry; 1994 Aug; 36(3):198-200. PubMed ID: 7948457
[No Abstract] [Full Text] [Related]
16. Methylphenidate challenge as a predictor of relapse in schizophrenia.
Lieberman JA; Kane JM; Gadaleta D; Brenner R; Lesser MS; Kinon B
Am J Psychiatry; 1984 May; 141(5):633-8. PubMed ID: 6143506
[TBL] [Abstract][Full Text] [Related]
17. A double-blind controlled study of intramuscular zuclopenthixol acetate and liquid oral haloperidol in the treatment of schizophrenic patients with acute exacerbation.
Chouinard G; Safadi G; Beauclair L
J Clin Psychopharmacol; 1994 Dec; 14(6):377-84. PubMed ID: 7884017
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia.
Kasper S; Lerman MN; McQuade RD; Saha A; Carson WH; Ali M; Archibald D; Ingenito G; Marcus R; Pigott T
Int J Neuropsychopharmacol; 2003 Dec; 6(4):325-37. PubMed ID: 14609439
[TBL] [Abstract][Full Text] [Related]
19. CSF diazepam binding inhibitor and schizophrenia: clinical and biochemical relationships.
van Kammen DP; Guidotti A; Kelley ME; Gurklis J; Guarneri P; Gilbertson MW; Yao JK; Peters J; Costa E
Biol Psychiatry; 1993 Oct; 34(8):515-22. PubMed ID: 8274578
[TBL] [Abstract][Full Text] [Related]
20. Comparison of withdrawal of typical and atypical antipsychotic drugs: a case study.
Alphs LD; Lee HS
J Clin Psychiatry; 1991 Aug; 52(8):346-8. PubMed ID: 1869497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
